Karpatkin S, Finlay T H, Ballesteros A L, Karpatkin M
Blood. 1987 Sep;70(3):773-8.
Prothrombin synthesis and secretion were studied in a human hepatoma cell line (Hep G2) incubated with 35S-methionine for 2 to 24 hours at 37 degrees C. Extracellular and intracellular prothrombin were detected by immunoprecipitation with affinity-purified antiprothrombin antibody. Incorporation of 35S-methionine into prothrombin was monitored by counting specific bands excised from 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). Prothrombin represented 0.3% to 0.7% of total newly synthesized protein secreted into the media. Warfarin had no effect on total prothrombin synthesis (extracellular plus intracellular). However, warfarin inhibited secretion of newly synthesized prothrombin by 58% to 73% over a 2 to 4 hour period. This was accompanied by the intracellular accumulation of an immunoprecipitable species of prothrombin of 78 kd, 6 kd less than extracellular prothrombin. At the end of the 4-hour incubation with warfarin, intracellular prothrombin increased from 44% to 82% (twofold) of total prothrombin, whereas extracellular prothrombin decreased from 56% to 19% (threefold) of total prothrombin. After 24-hour incubation with warfarin, intracellular and extracellular immunoprecipitable prothrombin approached control values. Deglycosylation of extracellular and intracellular prothrombin with hydrofluoric acid (HF) resulted in a decrease in mol wt for both species to 66 kd. Endoglycosidase-H treatment, which digests "early mannosyl" residues, resulted in a decrease in the mol wt of the intracellular species of 8 kd with no effect on the extracellular species. Thus, the lower mol wt intracellular species that accumulates following early warfarin treatment is due to the presence of incompletely processed carbohydrate chain. The data are compatible with the hypothesis that optimum glycosylation and secretion require Vitamin K-dependent carboxylation.
在37℃下,用35S-甲硫氨酸孵育人肝癌细胞系(Hep G2)2至24小时,研究凝血酶原的合成与分泌。用亲和纯化的抗凝血酶原抗体通过免疫沉淀法检测细胞外和细胞内的凝血酶原。通过对从10%十二烷基硫酸钠-聚丙烯酰胺凝胶电泳(SDS-PAGE)切下的特定条带进行计数,监测35S-甲硫氨酸掺入凝血酶原的情况。凝血酶原占分泌到培养基中的新合成蛋白质总量的0.3%至0.7%。华法林对凝血酶原的总合成(细胞外加细胞内)没有影响。然而,在2至4小时内,华法林抑制新合成凝血酶原的分泌达58%至73%。这伴随着细胞内一种78kd的可免疫沉淀的凝血酶原物种的积累,比细胞外凝血酶原少6kd。在用华法林孵育4小时结束时,细胞内凝血酶原从总凝血酶原的44%增加到82%(两倍),而细胞外凝血酶原从总凝血酶原的56%下降到19%(三倍)。用华法林孵育24小时后,细胞内和细胞外可免疫沉淀的凝血酶原接近对照值。用氢氟酸(HF)对细胞外和细胞内凝血酶原进行去糖基化处理,导致两种物种的分子量均降至66kd。内切糖苷酶-H处理可消化“早期甘露糖基”残基,导致细胞内物种的分子量降低8kd,而对细胞外物种没有影响。因此,早期华法林处理后积累的分子量较低的细胞内物种是由于存在未完全加工的碳水化合物链。这些数据与最佳糖基化和分泌需要维生素K依赖性羧化的假设相符。